Pfizer’s Q3 2025 earnings fell despite beating estimates. Weak growth and a stagnant outlook keep PFE stock a Hold.
Palantir (PLTR) delivered strong Q3 results, beating expectations on revenue, earnings, and Rule of 40, with robust growth in both government and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback